Literature DB >> 33737513

Bioprospecting of the agaricomycete Ganoderma australe GPC191 as novel source for L-asparaginase production.

Meghna Chakraborty1, Srividya Shivakumar2.   

Abstract

L-Asparaginase is a therapeutically and industrially-competent enzyme, acting predominantly as an anti-neoplastic and anti-cancerous agent. The existing formulations of prokaryotic L-asparaginase are often toxic and contain L-glutaminase and urease residues, thereby increasing the purification steps. Production of L-glutaminase and urease free L-asparaginase is thus desired. In this research, bioprospecting of isolates from the less explored class Agaricomycetes was undertaken for L-asparaginase production. Plate assay (using phenol red and bromothymol blue dyes) was performed followed by estimation of L-asparaginase, L-glutaminase and urease activities by Nesslerization reaction for all the isolates. The isolate displaying the desired enzyme production was subjected to morphological, molecular identification, and phylogenetic analysis with statistical validation using Jukes-Cantor by Neighbour-joining tree of Maximum Likelihood statistical method. Among the isolates, Ganoderma australe GPC191 with significantly high zone index value (5.581 ± 0.045 at 120 h) and enzyme activity (1.57 ± 0.006 U/mL), devoid of L-glutaminase and urease activity was selected. The present study for the first-time reported G. australe as the potential source of L-glutaminase and urease-free L-asparaginase and also is one of the few studies contributing to the literature of G. australe in India. Hence, it can be postulated that it may find its future application in pharmaceutical and food industries.

Entities:  

Year:  2021        PMID: 33737513     DOI: 10.1038/s41598-021-84949-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  4 in total

1.  PEGylated versus non-PEGylated drugs: A cross-sectional analysis of adverse events in the FDA Adverse Event Reporting System (FAERS) Database
.

Authors:  Zhengyi Zhu; Peng Gao; Yan Hu; Junyan Wang; Huijuan Wang; Jufei Yang; Lingfei Huang; Cai Ji; Yinghua Ni; Luo Fang
Journal:  Int J Clin Pharmacol Ther       Date:  2020-06       Impact factor: 1.366

2.  Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.

Authors:  Wellington F da Silva; Ires H B Massaut; Rodrigo M Bendlin; Lidiane I Rosa; Elvira D R P Velloso; Eduardo M Rego; Vanderson Rocha
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-04-13

3.  Hyperammonemia: What Urea-lly Need to Know: Case Report of Severe Noncirrhotic Hyperammonemic Encephalopathy and Review of the Literature.

Authors:  Ruby Upadhyay; Thomas P Bleck; Katharina M Busl
Journal:  Case Rep Med       Date:  2016-09-21

Review 4.  Golden Needle Mushroom: A Culinary Medicine with Evidenced-Based Biological Activities and Health Promoting Properties.

Authors:  Calyn Tang; Pearl Ching-Xin Hoo; Loh Teng-Hern Tan; Priyia Pusparajah; Tahir Mehmood Khan; Learn-Han Lee; Bey-Hing Goh; Kok-Gan Chan
Journal:  Front Pharmacol       Date:  2016-12-07       Impact factor: 5.810

  4 in total
  1 in total

Review 1.  Overview of the structure, side effects, and activity assays of l-asparaginase as a therapy drug of acute lymphoblastic leukemia.

Authors:  Nanxiang Wang; Wenhui Ji; Lan Wang; Wanxia Wu; Wei Zhang; Qiong Wu; Wei Du; Hua Bai; Bo Peng; Bo Ma; Lin Li
Journal:  RSC Med Chem       Date:  2022-01-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.